CCS Research & Mission
Translational Cancer Research at CCS:
Tumor-Microenvironment and Immune System Interactions
Cancer is a highly complex disease caused by genetic and epigenetic alterations in a normal healthy cell. Understanding the high degree of complexity on a molecular level is key to targeted and successful therapies and potentially curative treatments. This requires joint efforts of clinicians and molecular cancer biologists to identify the causes of malignant cell growth and to swiftly translate basic knowledge into clinical application.
The major scientific focus of CCS is on the understanding of intricate cellular communication processes between malignant cells, their microenvironment and the immune system during cancer growth, metastasis and the development of drug resistance.
Unraveling the molecular details of tumor-microenvironment interactions, in particular the mapping of oncogenic driver signals within the complex tumor micromilieu will provide new opportunites for innovative and improved therapeutic concepts tackling the most imminent therapeutic challenges such as relapse, metastasis and drug resistance to prolong patients´ survival.
CCS has been founded as an interdisciplinary consortium of 16 expert groups of the Salzburg Cancer Research Institute (SCRI), the Paris-Lodron University of Salzburg (PLUS) and the Paracelsus Medical University Clinics Salzburg (SALK/PMU). CCS provides an innovative research network of oncologists, molecular tumor biologists, immunologists and pathologists focusing on the development of novel and superior multi-modal treatments to increase survival and improve the quality of life.
Translational cancer research at CCS
Bench-to-bedside and bedside-to-bench work
The scientific strategy and conceptual organization of CCS allows both the validation of basic research findings in clinical settings (bench to bedside) and the detailed molecular analysis of clinical observations in predictive in vitro and in vivo model systems (bedside to bench). This bidirectional research strategy accelerates the discovery of novel and innovative therapeutic approaches for personalized cancer therapy.